Drug Approval | March 31, 2026
Teva hits major biosimilar milestones with FDA nod and regulatory filings
The US FDA has approved PONLIMSI (denosumab-adet) as a biosimilar to Prolia
The US FDA has approved PONLIMSI (denosumab-adet) as a biosimilar to Prolia
At 34 weeks, Ultomiris achieved a 43.4% placebo-adjusted reduction in 24-hour urine protein creatinine ratio (UPCR) versus placebo, meeting the study’s key interim endpoint
Revenue from operations climbed 13% to Rs. 886.87 crore
The development comes as stroke remains one of the world’s biggest health threats
Pharma major to engage with institutional investors through group meetings in Mumbai and Singapore during May 2026
Proposed amalgamation now awaits NCLT approval; shareholders to receive 51 Torrent Pharma shares for every 100 JB Pharma shares held
The company informed stock exchanges that the appellate authority has set aside the GST demand along with applicable interest and penalty
Approval marks the second generic semaglutide clearance in Canada and strengthens OneSource’s position in complex injectable CDMO programs
Company plans to appeal against CGST order related to alleged inadmissible input tax credit claims
The US regulator conducted an inspection at the Amaliya manufacturing plant between April 20 and May 1, 2026
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
